Bicalutamide Market: Size, Share, Growth, Analysis, Key Players, Revenue, Growth | Valuates Reports

Bicalutamide Market
Bicalutamide is a non-steroidal antiandrogenic drug, which is used in combination with luteinizing hormone releasing hormone (LHRH) analogues or surgical orchiectomy in the treatment of advanced prostate cancer.Bicalutamide first by oral absorption good.There is no pharmacodynamic or pharmacokinetic interaction with luteinizing hormone releasing hormone (LHRH) analogues.No interaction with common prescription drugs.No enzyme induction was observed at doses up to 150 mg per day.
The global Bicalutamide market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-18Z7926/Global_Bicalutamide_Market_Insights_and_Forecast_to_2028

North American market for Bicalutamide is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Bicalutamide is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Bicalutamide include AstraZeneca, CORDEN PHARMA GMBH, Zeneca GmbH, Actavis Pharma, Sivem Pharmaceuticals, Sorres Pharma, Fresenius Kabi, ANI Pharmaceuticals and Accel Pharma, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bicalutamide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bicalutamide.
The Bicalutamide market size, estimations, and forecasts are provided in terms of sales volume (M Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bicalutamide market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bicalutamide manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

Get regional report
https://reports.valuates.com/request/regional/QYRE-Auto-18Z7926/Global_Bicalutamide_Market_Insights_and_Forecast_to_2028

Segment by Type
• Tablets
• Capsule

Segment by Application
• Single Drug For Prostate Cancer
• Combined Chemotherapy For Prostate Cancer
• Combined Radiation Therapy Or Castration For Prostate Cancer

By Company
AstraZeneca, CORDEN PHARMA GMBH, Zeneca GmbH, Actavis Pharma, Sivem Pharmaceuticals, Sorres Pharma, Fresenius Kabi, ANI Pharmaceuticals, Accel Pharma, Apotex Corporation, Shanghai Fudan Fuhua Pharmaceutical, Shanghai Zhaohui Pharmaceutical, Zhejiang Haizheng Pharmaceutical, Shanxi Zhendong Pharmaceutical

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-18Z7926/global-bicalutamide

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.